Remdesivir
{{Drugbox | IUPAC_name = (2S)-2-{(2R,3R,4S,5R)-[5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(S)-phosphorylamino}propionic acid 2-ethyl-butyl ester | image = GS-5734_structure.png | tradename =GS-5734 | legal_status = Investigational New Drug
| bioavailability = | metabolism = | elimination_half-life = | excretion =
| CAS_number_Ref = 
| CAS_number = 1809249-37-3
| PubChem =
| UNII_Ref =
| UNII =
| DrugBank_Ref =
| ChemSpiderID =
| C=27 | H=35 | N=6 | O=8 | P=1 | molecular_weight = 602.575 | SMILES = Nc3ncnn2c3ccc2C(C#N)(C1O)OC(C1O)CO[P](=O)(NC(C)C(=O)OCC(CC)CC)Oc4ccccc4 }}
GS-5734 is an antiviral drug, a novel nucleotide analog prodrug. It was developed by Gilead Sciences as a treatment for filovirus infections such as Ebola virus disease and Marburg virus, though it has subsequently also been found to show reasonable antiviral activity against more distantly related viruses such as respiratory syncytial virus, Junin virus, Lassa fever virus, and MERS-coronavirus. GS-5734 was rapidly pushed through clinical trials due to the 2013–2016 West African Ebola virus epidemic crisis, eventually being used in at least one human patient despite its early development stage at the time. Preliminary results have been promising, and further clinical trials are planned.[1][2][3][4]
See also
References
- ^ Tomas Cihlar, Gilead Sciences. Discovery and Development of GS-5734, a Novel Nucleotide Prodrug with Broad Spectrum Anti-Filovirus Activity. FANG-WHO Workshop, Fort Detrick, MD. 20 October 2015
- ^ "Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates". Open Forum Infect Dis. 2. Fall 2015. doi:10.1093/ofid/ofv130.02 (inactive 2016-11-27).
{{cite journal}}: CS1 maint: DOI inactive as of November 2016 (link) CS1 maint: year (link) - ^ Warren, T. K.; Jordan, R; Lo, M. K.; Ray, A. S.; MacKman, R. L.; Soloveva, V; Siegel, D; Perron, M; Bannister, R; Hui, H. C.; Larson, N; Strickley, R; Wells, J; Stuthman, K. S.; Van Tongeren, S. A.; Garza, N. L.; Donnelly, G; Shurtleff, A. C.; Retterer, C. J.; Gharaibeh, D; Zamani, R; Kenny, T; Eaton, B. P.; Grimes, E; Welch, L. S.; Gomba, L; Wilhelmsen, C. L.; Nichols, D. K.; Nuss, J. E.; et al. (2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–5. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMID 26934220.
- ^ Jacobs, M; Rodger, A; Bell, D. J.; Bhagani, S; Cropley, I; Filipe, A; Gifford, R. J.; Hopkins, S; Hughes, J; Jabeen, F; Johannessen, I; Karageorgopoulos, D; Lackenby, A; Lester, R; Liu, R. S.; MacConnachie, A; Mahungu, T; Martin, D; Marshall, N; Mepham, S; Orton, R; Palmarini, M; Patel, M; Perry, C; Peters, S. E.; Porter, D; Ritchie, D; Ritchie, N. D.; Seaton, R. A.; et al. (2016). "Late Ebola virus relapse causing meningoencephalitis: a case report". Lancet. 388 (10043): 498–503. doi:10.1016/S0140-6736(16)30386-5. PMC 4967715. PMID 27209148.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |